Stock Market Reviews

Read and share opinions on CRMD (CorMedix Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock market.

Latest News

• Can CorMedix's Melinta Acquisition Aid Growth Beyond DefenCath?
  Dec 26, 2025
• CorMedix (CRMD): Assessing Valuation After a Strong Multi‑Year Share Price Run
  Dec 25, 2025
• CorMedix Therapeutics Announces Positive Data From Ongoing Real World Evidence Study of DefenCath
  Dec 18, 2025

CRMD News

• MNMD Stock Up More Than 100% in 6 Months: What's in Store for 2026?
  MNMD has surged 101% in six months with MM120 advancing in phase III for GAD and MDD. Pivotal readouts are slated for 2026.
  Dec 29, 2025
• Ocugen Stock Surges 75% Year to Date: What's in Store for 2026?
  Ocugen rises 75% YTD as it advances three gene therapies, with multiple phase II/III readouts and filings lined up for 2026.
  Dec 29, 2025
• Can CorMedix's Melinta Acquisition Aid Growth Beyond DefenCath?
  CRMD's $300M Melinta acquisition adds seven products and helps raise 2025 revenue guidance, but questions remain over easing DefenCath reliance.
  Dec 26, 2025
• CorMedix (CRMD): Assessing Valuation After a Strong Multi‑Year Share Price Run
  CorMedix (CRMD) has quietly been on a strong run, with shares up roughly 24% over the past month and about 48% year to date. This performance has put fresh attention on this kidney infection focused biotech. See our latest analysis for CorMedix. With the share price now at $12.19 and a 30 day share price return of 24.13 percent feeding into a 48.30 percent year to date share price gain, the move looks more like gathering momentum rather than a one off spike. This is especially the case when...
  Dec 25, 2025
• Sanofi to Buy Dynavax for $2.2B to Boost Adult Vaccine Franchise
  SNY's $2.2 billion deal for Dynavax adds Heplisav-B, a shingles candidate, and other vaccine programs, strengthening its adult vaccine franchise and pipeline.
  Dec 24, 2025
• AGIO's Mitapivat Gets FDA Nod for Thalassemia Indication with REMS in Label
  Agios Pharmaceuticals wins FDA approval for Aqvesme in alpha- and beta-thalassemia, making mitapivat the only approved option, despite a new REMS.
  Dec 24, 2025
• FDA Issues CRL to SNY's Regulatory Filing for Multiple Sclerosis Drug
  Sanofi receives an FDA CRL for tolebrutinib in nrSPMS after multiple review extensions. The EC clears Wayrilz for treating immune thrombocytopenia.
  Dec 24, 2025
• AZN, Daiichi's Enhertu Gets FDA Nod for First-Line Breast Cancer (Revised)
  AstraZeneca's Enhertu wins FDA nod as a first-line treatment for HER2-positive metastatic breast cancer.
  Dec 23, 2025
• GILD Exercises Option to License Assembly Bio's Herpes Programs
  Gilead exercises its option to license ASMB's HSV programs for developing long-acting candidates, ABI-1179 & ABI-5366, for recurrent genital herpes.
  Dec 23, 2025
• Why CorMedix Could be the Biopharma Name to Watch Early in 2026
  CorMedix is a promising biopharma firm in the catheter lock solution space. Continued success for its top products could fuel significant growth into 2026.
  Dec 23, 2025
• BioMarin to Buy Rare Disease Drugmaker Amicus Therapeutics for $4.8B
  BMRN agrees to acquire FOLD for $4.8B, adding two growing rare disease drugs and a late-stage pipeline asset to its portfolio.
  Dec 22, 2025
• AZN, Daiichi's Enhertu Gets Breakthrough Tag for Expanded Cancer Use
  AstraZeneca's Enhertu wins FDA Breakthrough tag for expanded use in breast cancer, while a late-stage study on ceralasertib + Imfinzi in lung cancer misses its goal.
  Dec 22, 2025
• MarketBeat’s Top 5 Rated Small-Cap Stocks
  Small-cap stocks are regaining momentum as rate cuts and the end of quantitative tightening drive a renewed risk-on environment.
  Dec 22, 2025
• MRNA to Get CEPI Funding for Phase III Study on Pandemic Influenza Jab
  Moderna secures up to $54.3 million from CEPI to fund a pivotal phase III study of its mRNA-based H5 pandemic flu vaccine candidate, mRNA-1018.
  Dec 19, 2025
• Is It Too Late to Consider CorMedix After DefenCath Progress and Strong Price Gains?
  If you are looking at CorMedix and wondering whether the run up is already priced in or if there is still value on the table, you are in the right place. The stock has quietly put up some strong numbers, with shares up 1.5% over the last week, 18.3% over the last month, 45.0% year to date, and 201.0% over three years. Recent news around CorMedix has largely focused on progress with its lead asset DefenCath, including regulatory milestones and commercialization preparations that have shifted...
  Dec 19, 2025
• INSM Stock Plummets on Sinus Study Failure, Adds New Pipeline Asset
  Insmed sinks nearly 20% after Brinsupri failed a phase IIb sinus study, while the company adds a new monoclonal antibody asset to expand its pipeline.
  Dec 18, 2025
• SNY's Rare Disease Drug Efdoralprin Alfa Gets EMA's Orphan Drug Tag
  Sanofi gains EMA Orphan Drug status for efdoralprin alfa, a phase II biologic for AATD-related emphysema with promising dosing data.
  Dec 18, 2025
• CorMedix Therapeutics Announces Positive Data From Ongoing Real World Evidence Study of DefenCath
  DefenCath® demonstrated a 72% reduction in CRBSI and 70% reduction in hospitalizations secondary to CRBSIBERKELEY HEIGHTS, N.J., Dec. 18, 2025 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced interim results for the Company’s ongoing real-world evidence study being conducted in conjunction with U.S. Renal Care’s (USRC) use of DefenCath
  Dec 18, 2025
• CRMD vs. PBYI: Which Small-Cap Biotech Stock Is the Better Buy?
  CorMedix's DefenCath sales and Melinta deal raise growth stakes while Puma Biotechnology's Nerlynx-led breast cancer franchise aids growth.
  Dec 17, 2025
• RZLT Stock Plummets 79% Month to Date: Here's What You Need to Know
  Rezolute shares collapse 79% so far in December after a phase III hyperinsulinism study of its only pipeline candidate miss primary and key secondary endpoints.
  Dec 17, 2025
• FDA Grants Fast Track Designation to ADAG's Colorectal Cancer Drug
  Adagene jumps 13.8% after the FDA grants Fast Track Status to muzastotug with pembrolizumab for MSS metastatic colorectal cancer.
  Dec 17, 2025
• CHMP Backs EU Approval of MRNA's New COVID-19 Vaccine mNexspike
  CHMP backs EU approval of Moderna's next-generation mNexspike COVID-19 vaccine, with a final European Commission decision expected shortly.
  Dec 16, 2025
• KYTX Stock Rallies 23% on Upbeat Stiff Person Syndrome Study Data
  Kyverna Therapeutics shares jump 23% after a registrational phase II study of miv-cel meets primary and all secondary efficacy goals for treating stiff person syndrome.
  Dec 16, 2025
• AZN, Daiichi's Enhertu Gets FDA Nod for First-Line Breast Cancer
  AstraZeneca's Enhertu wins FDA nod as a first-line treatment for HER2-positive metastatic breast cancer.
  Dec 16, 2025
• SNY Stock Down on Double Trouble With Multiple Sclerosis Drug
  Sanofi shares slide after the FDA again delays its review of its MS drug tolebrutinib, and a phase III study fails to hit its primary endpoint.
  Dec 16, 2025
• CRMD Up More Than 40% YTD: Time to Buy, Sell or Hold the Stock?
  CorMedix surges on strong DefenCath uptake as sales climb while the Melinta acquisition expands and diversifies its commercial portfolio.
  Dec 11, 2025
• CorMedix (CRMD): Is the Market Mispricing This Underappreciated Anti-Infective Growth Story?
  CorMedix (CRMD) has quietly turned into a stock worth a closer look, with shares up about 4% over the past month and more than 40% year to date despite recent volatility. See our latest analysis for CorMedix. That move sits within a choppy but constructive trend, with the latest share price at $11.62 and a strong year to date share price return contrasting with still sizable three and five year total shareholder returns that suggest long term holders have been well rewarded but not...
  Dec 10, 2025
• Does CorMedix (CRMD) Have the Potential to Rally 68.74% as Wall Street Analysts Expect?
  The mean of analysts' price targets for CorMedix (CRMD) points to a 68.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
  Dec 9, 2025
• Agios Awaits Pyrukynd Decision in Thalassemia as FDA Misses Due Date
  AGIO faces uncertainty as the FDA misses its Dec. 7 deadline related to the sNDA for Pyrukynd in thalassemia and offers no new timeline.
  Dec 9, 2025
• PRAX Stock Skyrockets 520% in 3 Months: Here's What You Need to Know
  Praxis stock soars after late-stage data show strong efficacy for ulixacaltamide therapy in essential tremor and momentum builds toward an early-2026 regulatory filing.
  Dec 8, 2025
• Best Value Stocks to Buy for December 8th
  GM, CRMD and AER made it to the Zacks Rank #1 (Strong Buy) value stocks list on December 8, 2025.
  Dec 8, 2025
• New Strong Buy Stocks for December 8th
  VFF, CRMD, AER, GM and FIVE have been added to the Zacks Rank #1 (Strong Buy) List on December 8, 2025.
  Dec 8, 2025
• CorMedix (CRMD) Upgraded to Strong Buy: Here's What You Should Know
  CorMedix (CRMD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
  Dec 8, 2025
• Incyte's Rare Blood Cancer Therapy Gets FDA's Breakthrough Status
  INCY secures FDA Breakthrough Therapy status for INCA033989 after early data show rapid and sustained platelet normalization in essential thrombocythemia patients.
  Dec 8, 2025
• CAPR Stock Skyrockets 282% in a Week: Here's What You Need to Know
  Capricor Therapeutics stock soars after meeting key goals with statistical significance in a phase III study of deramiocel for Duchenne cardiomyopathy.
  Dec 5, 2025
• Can DefenCath Continue to Aid CorMedix's Long-Term Growth Ahead?
  CRMD's lead product, DefenCath, generates $167.6M in sales in the first nine months of 2025, with market exclusivity through 2033 likely to provide growth momentum.
  Dec 5, 2025
• Is CorMedix Stock Still Attractive After Strong Multi Year Gains And Recent Volatility In 2025
  If you are wondering whether CorMedix at around $10.64 is an overlooked opportunity or already priced for perfection, you are in the right place. The stock is up 29.4% year to date and 181.5% over three years, although the last month has seen a 4.7% pullback after a recent 8.5% gain over the past week. That kind of volatility has been driven by growing optimism around CorMedix's lead infection prevention asset and regulatory milestones that have shifted investor expectations. At the same...
  Dec 5, 2025
• ABSI Stock Up on Initiating Dosing in Androgenetic Alopecia Study
  Absci Corporation stock jumps after initiating dosing in its phase I/IIa ABS-201 study for androgenetic alopecia, seeking early safety and efficacy signals.
  Dec 5, 2025
• AZN's Baxdrostat Gets FDA Priority Tag for Uncontrolled Hypertension
  AstraZeneca's NDA for baxdrostat gains FDA priority review for treating hard-to-control hypertension. A decision is due in the second quarter of 2026.
  Dec 3, 2025
• PCRX's Iovera Outperforms RFA Therapy in Pilot Study for Low Back Pain
  Pacira BioSciences' iovera shows stronger, longer-lasting relief than RFA in a pilot CLBP study, highlighting its tissue-sparing approach and potential spine-care impact.
  Dec 3, 2025
• MIRM Enrolls First Patient in Phase II Fragile X Syndrome Study
  Mirum enrolls the first participant in its phase II BLOOM study investigating MRM-3379 for treating Fragile X syndrome.
  Dec 2, 2025
• ARCT Stock Plunges 59% in Three Months: Here's What You Need to Know
  Arcturus Therapeutics' stock slides 59%, primarily due to mixed interim results from the phase II study of its investigational inhaled cystic fibrosis therapy, ARCT-032.
  Dec 1, 2025
• SNY & REGN's Dupixent Gets EU Nod for Chronic Spontaneous Urticaria
  Sanofi/Regeneron's Dupixent wins EU nod for chronic spontaneous urticaria, marking its seventh approved indication across inflammatory diseases in the EU.
  Nov 25, 2025
• Assessing CorMedix (CRMD): Is the Current Share Price Reflecting Its True Value?
  CorMedix (CRMD) stock has been drawing attention as investors evaluate its recent performance trends. Over the past month, shares are down 12%. However, gains earlier this year still put the stock up nearly 20% year to date. See our latest analysis for CorMedix. CorMedix’s share price has pulled back sharply in the past month, with a 1-month share price return of -12%. However, the stock still holds on to solid year-to-date gains and has more than doubled investors’ capital over the past...
  Nov 25, 2025
• Cormedix Inc (CRMD) Q3 2025 Earnings Call Highlights: Record Financial Performance and ...
  Cormedix Inc (CRMD) reports robust Q3 results with increased revenue guidance and strategic growth through acquisitions, despite challenges in operating expenses and future pricing dynamics.
  Nov 21, 2025
• AGIO Stock Hits 52-Week Low on Mixed Sickle Cell Disease Study Results
  Agios slides to a 52-week low after mixed phase III RISE UP data show a hemoglobin boost but no significant cut in pain crises.
  Nov 20, 2025
• ALKS Raises Its Offer to Buy Avadel In Response to Lundbeck's Proposal
  Alkermes lifts its bid to buy Avadel for $22.50 per share as its takeover fight with Lundbeck intensifies and shifts the deal's momentum.
  Nov 20, 2025
• Insmed Stock Rise on EU Nod for Lung Disease Drug, Brinsupri
  INSM climbs after the EU clears Brinsupri as the first approved treatment for NCFB, backed by phase III ASPEN and phase II WILLOW results.
  Nov 19, 2025
• JAZZ Hits 52-Week High on Encouraging Gastric Cancer Study Data
  Jazz jumps to a 52-week high after HERIZON-GEA-01 shows Ziihera combos delivering meaningful PFS and OS gains in HER2+ GEA.
  Nov 18, 2025
• Does the Recent 9.9% Pullback Make CorMedix a Bargain in 2025?
  Wondering if CorMedix is a hidden value play or if the current price leaves no room for upside? You are not alone. Many investors are taking a fresh look at the stock's true worth. After a stellar 157.2% return over the last three years, shares have pulled back in the last week by 9.9%. Year-to-date performance remains strong at 21.4%. Some of this recent movement follows notable headlines. CorMedix has made strides with its flagship DefenCath product, particularly as regulatory milestones...
  Nov 18, 2025
• H.C. Wainwright Raises the PT on ​CorMedix Inc. (CRMD), Keeps a Buy
  ​CorMedix Inc. (NASDAQ:CRMD) is one of the Fast-Growing Small Cap Stocks to Buy According to Analysts. On November 13, H.C. Wainwright analyst Brandon Folkes reiterated a Buy rating on CorMedix Inc. (NASDAQ:CRMD) and raised the price target from $17 to $18. The improved positive outlook follows the company’s earnings beat during its fiscal Q3 2025. […]
  Nov 18, 2025
• Buy Rating Reaffirmed: CorMedix Inc. (CRMD) Posts Profitability and Expands Outlook for 2025
  CorMedix Inc. (NASDAQ:CRMD) is one of the best breakout stocks to invest in. On November 13, H.C. Wainwright’s Brandon Folkes reaffirmed a Buy on CorMedix Inc. (NASDAQ:CRMD), citing strong DefenCath-driven revenue, Melinta acquisition synergies, and multiple growth catalysts including Rezzayo and TPN Phase 3 data in 2026. Despite TDAPA pricing risks, robust financials and pipeline […]
  Nov 18, 2025
• Avadel Board Labels Lundbeck Acquisition Bid a Superior Proposal
  AVDL's board calls Lundbeck's higher $23-per-share bid superior to its Alkermes deal, triggering a critical five-day response window.
  Nov 18, 2025
• CorMedix’s (CRMD) Return to Profitability and ESOP Plan Might Change the Case For Investing
  CorMedix Inc. recently reported third quarter 2025 results showing sales of US$101.55 million and net income of US$108.56 million, a significant reversal from the net loss posted a year prior; the company also issued a new earnings guidance range of US$115–US$135 million for Q4 2025 and filed a shelf registration to potentially offer nearly 7.7 million shares. An interesting detail is that the shelf registration was connected to an employee stock ownership plan (ESOP), indicating an...
  Nov 14, 2025
• Talphera (TLPH) Q3 2025 Earnings Call Transcript
  Beyond the NIAID opportunity, the recent investments were catalyzed by our efforts at the end of last year to restructure the nephro clinical study, which included changing the target profile for clinical sites and investigators and approaching the FDA with various study protocol changes, including the reduction of the study size from 166 to 70 patients with a goal of accelerating the completion of the study. The results of this restructuring were evident last quarter with the acceleration in the enrollment rate from our existing sites, which continued into the third quarter.
  Nov 13, 2025
• CorMedix: Q3 Earnings Snapshot
  BERKELEY HEIGHTS, N.J. (AP) — CorMedix Inc. CRMD) on Wednesday reported third-quarter net income of $108.6 million. The Berkeley Heights, New Jersey-based company said it had net income of $1.26 per share.
  Nov 12, 2025
• CorMedix Inc. Reports Third Quarter 2025 Financial Results and Updates FY 2025 Guidance
  ‒ Q3 2025 Net Revenue of $104.3 million; Pro Forma Net Revenue of $130.8 million ‒ ‒ Q3 2025 Net Income of $108.6 million; Adjusted EBITDA of $71.9 million ‒ ‒ FY 2025 Pro Forma Net Revenue Guidance Raised to a Range of $390 to $410 million ‒ ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time ‒ BERKELEY HEIGHTS, N.J., Nov. 12, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-thr
  Nov 12, 2025
• Talphera Announces Third Quarter 2025 Financial Results and Provides Corporate Update
  Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced third quarter 2025 financial results and provided a corporate update.
  Nov 12, 2025
• Immunovant's Q2 Loss Wider Than Expected, Pipeline in Focus
  Immunovant posts a wider Q2 loss as R&D spending rises, but progress on IMVT-1402 and batoclimab fuels its pipeline momentum.
  Nov 11, 2025
• Wall Street Analysts Predict an 80.58% Upside in CorMedix (CRMD): Here's What You Should Know
  The mean of analysts' price targets for CorMedix (CRMD) points to an 80.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
  Nov 10, 2025
• Assessing CorMedix (CRMD) Valuation After Recent Momentum Pause and Melinta Therapeutics Acquisition
  CorMedix (CRMD) has caught some attention in recent weeks, with the stock making modest moves despite generally steady results. Investors are now weighing its year-to-date climb of 31% in comparison to its recent one month pause. See our latest analysis for CorMedix. CorMedix's momentum has slowed a bit after its strong climb earlier this year, with the share price largely holding steady over the past month. Even so, the stock is up 31% year-to-date, standing in sharp contrast to its 10.6%...
  Nov 10, 2025
• IOVA Soars 28% on Narrower-Than-Expected Loss in Q3, Revenues Up Y/Y
  Iovance's shares jump 28% as the biotech narrows its quarterly loss and lifts gross margins amid strong Amtagvi sales and cost cuts.
  Nov 7, 2025
• Allogene Posts Narrower-Than-Expected Loss in Q3, Nil Sales
  ALLO's Q3 loss narrows to 19 cents per share, beating estimates, as R&D and G&A costs decline despite no product sales.
  Nov 7, 2025
• JAZZ Beats on Q3 Earnings & Sales, Narrows '25 Sales View
  Jazz Pharmaceuticals posts strong Q3 results with higher EPS and sales, aided by a tax benefit and robust neuroscience growth.
  Nov 6, 2025
• Viatris Tops Q3 Earnings & Revenue Estimates, Ups '25 Guidance
  Viatris tops Q3 earnings and revenue estimates, lifts 2025 outlook, and expands its Japan presence with Aculys Pharma deal.
  Nov 6, 2025
• Revolution Medicines Posts Wider-Than-Expected Loss in Q3, Sales Nil
  RVMD posts a wider Q3 loss as rising R&D and administrative costs weigh, while its RAS(ON) pipeline advances toward key 2026 data.
  Nov 6, 2025
• Bet on 5 Top-Ranked Stocks With Rising P/E
  Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include The Chef's Warehouse, Life Time Group Holdings, The Honest Company, CorMedix and Boston Scientific.
  Nov 5, 2025
• Amicus' Q3 Earnings Beat, Higher Product Sales Drive Y/Y Revenues
  FOLD's third-quarter earnings top estimates as rising Galafold and Pombiliti + Opfolda sales lift revenues by 19% year over year.
  Nov 5, 2025
• New Strong Buy Stocks for November 4th
  CRMD, GWRE, TNET, UHS and ISBA have been added to the Zacks Rank #1 (Strong Buy) List on Nov. 4, 2025.
  Nov 4, 2025
• All You Need to Know About CorMedix (CRMD) Rating Upgrade to Strong Buy
  CorMedix (CRMD) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
  Nov 4, 2025
• Could the FDA Approval Spark a New Chapter for CorMedix in 2025?
  Ever wondered if CorMedix could be a hidden gem or is already priced for perfection? Let’s dig into what savvy investors are really seeing in this biotech stock right now. The stock has climbed an impressive 35.4% year-to-date and is up 16.1% over the past year. However, it saw a modest dip of 1.9% in the last month. Recent FDA approval for CorMedix’s DefenCath catheter lock solution has sparked optimism and helped drive the stock’s strong gains. Investor sentiment has been boosted by the...
  Nov 3, 2025
• CorMedix Inc. to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 12, 2025
  BERKELEY HEIGHTS, N.J., Oct. 31, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it will report its financial results for the third quarter ended September 30, 2025, before the market opens on Wednesday, November 12, 2025, and will host a corporate update conference call at 8:30am Eastern Time. Wednesday, November 12th @ 8:30am ETDom
  Oct 31, 2025
• CRMD vs. TBPH: Which Small-Cap Biotech Stock Is the Better Buy?
  CorMedix and Theravance take sharply different routes to small-cap biotech growth - one fueled by sales traction, the other by pipeline promise.
  Oct 30, 2025

CRMD Reviews

• CandleFreak

  Dec 29, 2025

  $CRMD Operating in the biopharmaceutical sector, this firm is innovating with a pipeline that addresses critical medical needs. Their ongoing research and development initiatives hold promise for addressing significant health challenges and expanding their market presence.

  Buy

• LazyQuant

  Dec 28, 2025

  $CRMD This company is like the superhero of health – swooping in to save the day with a trusty sidekick of solutions!

  Buy

• TradePulse

  Dec 28, 2025

  $CRMD In the biotech arena, every FDA announcement sends investors into a frenzy. The hope of breakthrough treatments clashes with the fear of setbacks. Are you ready for the emotional rollercoaster?

  Sell

• CashKiller

  Dec 27, 2025

  $CRMD More like 'Can't Read My Dividend' at this point.

  Sell

• CodeAndCapital

  Dec 27, 2025

  $CRMD Imagine if medicine had a superhero. Spoiler: it’s this company, fighting off the villains of health issues with style!

  Buy

• ProfitShade

  Dec 26, 2025

  $CRMD Healing vibes in the air, could change the game if played right.

  Buy

• PortfolioPunk

  Dec 26, 2025

  $CRMD In a sea of biotechs, this one is barely a ripple.

  Sell

• ShortSqueezeX

  Dec 25, 2025

  $CRMD If stocks were snacks, this one would be a protein bar—great for your health but not exactly the most exciting choice in the lunchbox!

  Sell

• VolatilityViper

  Dec 25, 2025

  $CRMD You have better odds at winning a lottery than this stock succeeding.

  Sell

• DividendDemon

  Dec 23, 2025

  $CRMD This stock is like a superhero for your health - swooping in to save the day one treatment at a time! 🦸‍♂️

  Buy

• CapitalCarnage

  Dec 23, 2025

  $CRMD If this is the future of healthcare, we're all doomed.

  Sell

• WallStreetHex

  Dec 23, 2025

  $CRMD This company is at the forefront of developing innovative therapies that address significant unmet medical needs. With a strong pipeline and strategic partnerships, it appears well-positioned to capitalize on upcoming market opportunities.

  Buy

• GammaGrind

  Dec 23, 2025

  $CRMD Aiming to innovate, but gotta watch for that competition heat!

  Sell

• MoonBagz

  Dec 23, 2025

  $CRMD Health game is strong, might just be the remedy you didn't know you needed.

  Buy

• BagholderPrime

  Dec 23, 2025

  $CRMD This one feels like a diet soda – promising but sometimes leaves you feeling a bit flat!

  Sell

• PortfolioGremlin

  Dec 22, 2025

  $CRMD Medicinal magic in play, watch out for this one!

  Buy

• TendieTitan

  Dec 22, 2025

  $CRMD Think of this stock as a doctor—prescribing you healthy gains with a side of profits!

  Buy

• WallStreetWraith

  Dec 21, 2025

  $CRMD This one’s more hype than substance, good luck with that.

  Sell

• TraderFury

  Dec 21, 2025

  $CRMD With healthcare needs soaring, the pressure is on! Will this company deliver lifesaving solutions or find itself drowning in adversity?

  Sell

• VolatileViking

  Dec 19, 2025

  $CRMD This stock is like the superhero of healthcare – fighting off illness one share at a time! It's got the cape and everything.

  Buy

• FinTechNomad

  Dec 19, 2025

  $CRMD Caught in an intense race for breakthroughs, will they outpace the competition, or are they destined for turbulence? The anticipation is almost too much to bear!

  Buy

• MarketDrift

  Dec 19, 2025

  $CRMD They’re all about that health hustle, big things brewing in the lab!

  Buy

• FiscalRiot

  Dec 19, 2025

  $CRMD The stakes in the healthcare sector are high, and the competition is fierce! One hiccup could derail everything—stay sharp!

  Sell

• DividendGhost

  Dec 18, 2025

  $CRMD The pressure is building as timelines stretch and results seem elusive. Stakeholders are nervously checking the latest updates, hoping for a spark.

  Sell

• GainVector

  Dec 18, 2025

  $CRMD This biotech firm is making strides in addressing unmet medical needs with its novel therapies. Their dedicated focus on patient outcomes may resonate well with investors interested in impactful healthcare solutions.

  Buy

• QuantumBroker

  Dec 18, 2025

  $CRMD The pressure is mounting as investors await crucial news! Will this stock shine bright or will it dim in the face of competition?

  Buy

• YieldMyth

  Dec 17, 2025

  $CRMD They got some serious healing vibes, ready to bounce back!

  Buy

• MarketReaper

  Dec 17, 2025

  $CRMD This company is like a superhero for meds—saving the day one patient at a time! Who knew health care could be so heroic?

  Buy

• MarketMatrix

  Dec 17, 2025

  $CRMD When it comes to health, this company is like the secret sauce—keeping things in check and making everything taste better!

  Buy

• TradeHex

  Dec 17, 2025

  $CRMD Focusing on groundbreaking therapies, this company is making significant strides in the pharmaceutical industry. Its dedication to addressing unmet medical needs sets it apart as a leader in innovation.

  Buy

• CashCraze

  Dec 16, 2025

  $CRMD With a focus on innovative solutions for difficult-to-treat infections, this firm is carving out a niche in the biotech space. Its dedication to research and development is indicative of a forward-thinking approach that could yield positive results.

  Buy

• QuantQuest

  Dec 16, 2025

  $CRMD Think of this stock as your favorite superhero—it’s here to save the day, but only if you can keep the cape on while flying!

  Buy

• CashCombo

  Dec 16, 2025

  $CRMD When it comes to health solutions, they’re like a medical ninja. Quiet, effective, and probably avoidant of hospitals!

  Buy

• DigitalDividend

  Dec 16, 2025

  $CRMD This stock is like finding a $20 bill in your pocket – unexpected and definitely worth a second glance! It might surprise you!

  Buy

• QuantAssault

  Dec 16, 2025

  $CRMD This company's making health look so easy, it's like they have a magic wand! Just don’t expect them to fix your broken heart.

  Buy

• HODLzilla

  Dec 15, 2025

  $CRMD This one’s got potential, just waiting for its moment to shine, you feel me?

  Buy

• BullishVanguard

  Dec 15, 2025

  $CRMD They say hope is not a strategy; they weren't joking.

  Sell

• QuantAssault

  Dec 15, 2025

  $CRMD Cures and mysteries – they’ve got the medical drama vibe down, but will they script a happy ending?

  Buy

• BearFighter

  Dec 15, 2025

  $CRMD Strong fundamentals backing this move.

  Buy

• MarketMyth

  Dec 15, 2025

  $CRMD Focused on innovative medical solutions, this firm is navigating a complex healthcare landscape with strategic partnerships and research initiatives. Its commitment to improving patient care positions it well for future success.

  Buy

• MarginBeast

  Dec 14, 2025

  $CRMD Another company more focused on the press release than profits.

  Sell

• FiscalRogue

  Dec 14, 2025

  $CRMD A small cap with a big ego but no substance.

  Sell

• MarketWolf

  Dec 13, 2025

  $CRMD This company is navigating a whirlwind of regulatory challenges that could either make or break its future. Investors are biting their nails waiting for the next announcement, and the tension is palpable!

  Sell

• VolatilityStrike

  Dec 13, 2025

  $CRMD Strong selloff continuation risk.

  Sell

• TradeProtocol

  Dec 12, 2025

  $CRMD This company is like that friend who always comes through for you—unexpectedly, but you're grateful they showed up!

  Buy

• HedgeKnight

  Dec 12, 2025

  $CRMD If this stock were a superhero, it’d definitely be saving the world one healthcare problem at a time! 🦸‍♂️

  Buy

• IndexPredator

  Dec 12, 2025

  $CRMD In the competitive field of healthcare, this firm must stand out amid rising pressures and new regulations. Success could redefine their future, but failure could spell disaster!

  Buy

• BuyLowBoi

  Dec 12, 2025

  $CRMD Market signaling deeper correction.

  Sell

• MarginMythic

  Dec 12, 2025

  $CRMD Breakout continuation likely.

  Buy

• CapitalVortex

  Dec 12, 2025

  $CRMD Downside continuation formation.

  Sell

• BullishSniper

  Dec 12, 2025

  $CRMD Breakout traps shorts — bullish outcome ahead.

  Buy

• GainMachine

  Dec 11, 2025

  $CRMD This stock is like a medicinal herb – sounds soothing, but you might want to consult a doctor first!

  Sell

• OptionOverlord

  Dec 11, 2025

  $CRMD CorMedix? They’re probably remedying the situation with a side of laughter. Because who doesn’t like a good joke with their meds?

  Buy

• BullishSniper

  Dec 11, 2025

  $CRMD High selling interest observed.

  Sell

• TradePredator

  Dec 11, 2025

  $CRMD Bearish potential increasing fast.

  Sell

• QuantSpecter

  Dec 11, 2025

  $CRMD Powerful continuation setup.

  Buy

• DiamondHandz

  Dec 11, 2025

  $CRMD Bullish multi-timeframe alignment.

  Buy

• AlphaDecoder

  Dec 11, 2025

  $CRMD Bullish cross on key indicators.

  Buy

• ShortSqueezeX

  Dec 11, 2025

  $CRMD Chart showing explosive potential.

  Buy

• TradeProtocol

  Dec 10, 2025

  $CRMD This company is like the underdog of the medical world—root for them, and they just might surprise you!

  Buy

• BearEater

  Dec 9, 2025

  $CRMD With its advancements in medical technology, this firm is positioned to make a significant impact in patient care. Their innovative approach addresses critical healthcare needs, attracting attention from industry stakeholders.

  Buy

• CapitalVortex

  Dec 9, 2025

  $CRMD This one’s like walking a tightrope over uncertainty! Every bit of news feels monumental, and the stakes couldn't be higher. Are you ready for the next leap of faith?

  Buy

• HedgeKnight

  Dec 9, 2025

  $CRMD Bullish breakout imminent.

  Buy

• BearMarketSurvivor

  Dec 9, 2025

  $CRMD This one's got the hustle, keep your eye on it!

  Buy

• EquityAssault

  Dec 9, 2025

  $CRMD Chart looks extremely fragile.

  Sell

• MarginDagger

  Dec 9, 2025

  $CRMD This company is making significant strides in the biopharmaceutical sector, focusing on innovative treatments that address unmet medical needs. With a strong pipeline and strategic partnerships, it has the potential to capture market interest and drive long-term growth.

  Buy

• YieldWarden

  Dec 9, 2025

  $CRMD Bearish potential increasing fast.

  Sell

• BullishVanguard

  Dec 9, 2025

  $CRMD Momentum strongly bearish.

  Sell

• QuantQuest

  Dec 8, 2025

  $CRMD They're on a mission to make medicine cooler—like superheroes but with lab coats!

  Buy

• RiskAssassin

  Dec 7, 2025

  $CRMD The breakthroughs in this niche market promise hope, but the stakes are high. Can they manage investor expectations without faltering? The ticking clock adds to the urgency here.

  Buy

• TrendHunter

  Dec 7, 2025

  $CRMD Health gimmicks won't save this sinking ship.

  Sell

• MarginMythic

  Dec 7, 2025

  $CRMD The pharmaceutical industry is fraught with challenges! Regulatory hurdles and market competition could make or break this company’s future. Will it rise to the occasion or face setbacks?

  Sell

• OptionOutlaw

  Dec 7, 2025

  $CRMD An underperformer that makes the rest look good.

  Sell

• PortfolioPunk

  Dec 6, 2025

  $CRMD Boring in a world full of excitement is a surefire way to lose.

  Sell

• ProfitVortex

  Dec 5, 2025

  $CRMD If this medical stock had a highlight reel, it would definitely involve some dramatic music and epic slow-motion shots of breakthroughs!

  Buy

• TrendHunter

  Dec 5, 2025

  $CRMD Hoping for a breakthrough, but reality says otherwise.

  Sell

• FiscalFrost

  Dec 4, 2025

  $CRMD Lower timeframe collapse forming.

  Sell

• DividendVortex

  Dec 4, 2025

  $CRMD Strongest bullish pattern I've seen today.

  Buy

• ShortKingston

  Dec 3, 2025

  $CRMD Imagine a superhero for healthcare—this stock is fighting off all the bad vibes in the industry!

  Buy

• OptionMatrix

  Dec 2, 2025

  $CRMD This company is making strides in healthcare innovation, particularly in addressing unmet medical needs. Their focused research efforts show potential for breakthroughs in patient care.

  Buy

• TheGainReaper

  Dec 2, 2025

  $CRMD A risky gamble that could leave you holding the bag.

  Sell

• CashCombo

  Dec 1, 2025

  $CRMD Their solutions could be the superhero we didn’t know we needed—saving lives one treatment at a time!

  Buy

• CashOverload

  Dec 1, 2025

  $CRMD A stock with a pipeline so dry, it could use a rain dance.

  Sell

• IndexPredator

  Dec 1, 2025

  $CRMD The biomedical field is rife with challenges, and this company faces a critical moment. Can their breakthroughs be enough to secure their place?

  Sell

• MarketWolf

  Dec 1, 2025

  $CRMD With significant advancements on the horizon, the anticipation is electrifying! However, the pressure to deliver positive news can be overwhelming. Is the team ready to face the inevitable scrutiny?

  Buy

• LiquidKnight

  Dec 1, 2025

  $CRMD Every day feels like a new chapter for this stock! The drama is intense, and keeping up with the twists and turns has investors on the edge of their seats. What’s coming next?

  Buy

• AlphaDecoder

  Nov 30, 2025

  $CRMD With a focus on improving patient outcomes through novel therapies, this biotech firm is addressing significant unmet medical needs. Its dedication to research and development could lead to breakthroughs that resonate with the healthcare community.

  Buy

• VolatilityViper

  Nov 30, 2025

  $CRMD Innovative? Maybe. Profitable? Keep dreaming.

  Sell

• TradeNinja

  Nov 30, 2025

  $CRMD This company might just be the secret sauce in the health world! If only it came with a side of fries.

  Buy

• PortfolioPunk

  Nov 30, 2025

  $CRMD Another one that’s all talk and no action.

  Sell

• TradeRebel

  Nov 29, 2025

  $CRMD In the race to innovate, this company is in the thick of it. But the pressure is mounting, and only time will tell if it can deliver on its promises!

  Sell

• FiscalEngine

  Nov 29, 2025

  $CRMD This firm is pioneering medical advancements with its focus on innovative therapies. Their dedication to improving patient outcomes and addressing unmet medical needs may create significant opportunities in the healthcare market.

  Buy

• QuantSpecter

  Nov 28, 2025

  $CRMD The pressure is on in the biotech space—results need to come through soon or the stakes will only get higher. Investors are biting their nails waiting for news!

  Sell

• OptionOverlord

  Nov 28, 2025

  $CRMD This stock is like a rare Pokémon—hard to catch but worth the effort when you finally evolve it!

  Sell

• TickerTakedown

  Nov 28, 2025

  $CRMD This stock is like that underdog in a superhero movie—everyone's rooting for it to save the day!

  Buy

• BearFighter

  Nov 28, 2025

  $CRMD This stock’s progress is slower than a turtle on vacation.

  Sell

• LazyQuant

  Nov 28, 2025

  $CRMD Like a solid wifi connection, this company aims to keep your health in check without dropping the signal. Stay connected, folks!

  Buy

• TradeBlitz

  Nov 28, 2025

  $CRMD With their focus on medicine, they're like the superhero team for your immune system, minus the capes!

  Buy

• ChartFang

  Nov 27, 2025

  $CRMD Focused on offering critical solutions in healthcare, this firm is developing therapies that address unmet medical needs. Their pipeline and research capabilities highlight their potential to make a substantial impact.

  Buy

• BuyLowBro

  Nov 27, 2025

  $CRMD If this stock were a character, it’d be the quirky friend who always has the craziest ideas but somehow makes them work!

  Sell

• EquityAssault

  Nov 26, 2025

  $CRMD If you’re looking for failure, this is the gold standard.

  Sell

• CashCombo

  Nov 26, 2025

  $CRMD This stock might need a little CPR—it’s going to need some serious love to keep breathing!

  Sell

• HODLWarrior

  Nov 24, 2025

  $CRMD This crew's got some serious hustle in the healthcare scene, don’t sleep on 'em!

  Buy

• FiscalEngine

  Nov 24, 2025

  $CRMD This biopharmaceutical company is working on critical therapeutics that address significant health challenges. Their dedication to innovation and meeting patient needs may drive future growth and impact healthcare outcomes positively.

  Buy

• TrendScript

  Nov 23, 2025

  $CRMD With a focus on innovative therapies for serious medical conditions, this company is paving the way for advancements in patient treatment. Its clinical pipeline reflects a commitment to addressing unmet needs in healthcare, promising future growth.

  Buy

• TheGainReaper

  Nov 23, 2025

  $CRMD Hope is not a strategy, and this stock proves it.

  Sell

• TrendStalker

  Nov 23, 2025

  $CRMD If only your performance matched your ambition.

  Sell

• TheEquityEdge

  Nov 22, 2025

  $CRMD With a clear emphasis on addressing severe health challenges, this company is leveraging unique treatment options that could significantly improve patient outcomes. Their niche market focus suggests potential for growth.

  Buy

• RiskAssassin

  Nov 22, 2025

  $CRMD This one's making waves in the healthcare sector, but the competition is fierce! Are you feeling the pressure to jump in before it skyrockets or risks crashing down?

  Buy

• GainsGoblin

  Nov 21, 2025

  $CRMD This one’s got mad potential, keep an eye on it!

  Buy

• QuantQuest

  Nov 21, 2025

  $CRMD Like trying to make a viral video happen—takes effort, and results might vary, but hey, hope springs eternal!

  Sell

• HedgeMeNot

  Nov 20, 2025

  $CRMD In the medical zone, keep it under the radar but it’s sneaky good!

  Buy

• TheStockKnight

  Nov 19, 2025

  $CRMD This stock is about as exciting as watching paint dry.

  Sell

• BullBrawler

  Nov 18, 2025

  $CRMD An underdog that just can’t seem to find its footing. Might want to rethink that strategy.

  Sell

• OptionOverlord

  Nov 18, 2025

  $CRMD This stock is like that underdog in a movie—full of potential and just waiting for its big moment!

  Buy

• CodeTrader

  Nov 18, 2025

  $CRMD The pressure is on for this player in the healthcare arena! One misstep could mean disaster, but a breakthrough might just be around the corner. Will they rise or fall?

  Buy

• ManiaBroker

  Nov 17, 2025

  $CRMD If this company can cure my fear of public speaking, I might just start a TED Talk series! Just kidding, I’m still terrified.

  Sell

• LiquidLegend

  Nov 16, 2025

  $CRMD I’d say this one’s got a heart of gold—hard to find and definitely worth a look!

  Buy

• YieldMyth

  Nov 15, 2025

  $CRMD Healing vibes in the air, watch this one closely!

  Buy

• MarketMyth

  Nov 15, 2025

  $CRMD This biotech firm is committed to addressing critical health challenges through its innovative therapeutic solutions. Positive developments in its research could have far-reaching implications for the healthcare community and investor interest.

  Buy

• ByteBull

  Nov 14, 2025

  $CRMD This company is like that friend who always has the best band-aids for your life’s oopsies!

  Sell

• DividendDemon

  Nov 13, 2025

  $CRMD This company's got the medical industry on speed dial—perfect for those who need a little extra TLC!

  Buy

• CashClown

  Nov 13, 2025

  $CRMD They out here fightin' hard, makin' moves in the game!

  Buy

• CodeAndCapital

  Nov 12, 2025

  $CRMD This stock is like my science project: it’s got potential, but I’m still waiting for it to stick together!

  Sell

• HedgeMeNot

  Nov 12, 2025

  $CRMD This joint got potential, just watch it blow up, ya feel me?

  Buy

• FUDCrusher

  Nov 11, 2025

  $CRMD This health game’s strong, got the potential to heal and steal the show!

  Buy

• BullBrawler

  Nov 11, 2025

  $CRMD Chasing miracles in medicine, but mostly just chasing its tail.

  Sell

• TradeSaber

  Nov 11, 2025

  $CRMD Watch out, this player’s makin' big moves, ya dig?

  Buy

• ChartCrusher

  Nov 11, 2025

  $CRMD A classic case of overhyped mediocrity, enjoy the ride down.

  Sell

• GammaGrind

  Nov 11, 2025

  $CRMD Keep an eye on this one, could be the underdog that surprises everyone!

  Buy

• MarketGlitch

  Nov 10, 2025

  $CRMD When it comes to pharmaceuticals, the stakes are high and the timeline is tight. One miscalculation could derail everything!

  Sell

• BuyLowBoi

  Nov 10, 2025

  $CRMD This one's got major hustle, keep your eyes peeled for the next move!

  Buy

• PaperHandsGone

  Nov 9, 2025

  $CRMD Kinda risky, but could flip the script if it plays its cards right.

  Sell

• BuyLowBoi

  Nov 9, 2025

  $CRMD Watch out, they’re playing the long game and it’s looking good!

  Buy

• MoonBagz

  Nov 9, 2025

  $CRMD Playing hard in the healthcare hood, respect the grind!

  Buy

• Stonks4Days

  Nov 8, 2025

  $CRMD With a focus on healing, they’re making waves in the health scene!

  Buy

• BearMarketSurvivor

  Nov 8, 2025

  $CRMD keeping today passed beastly pumping clean heating patience here smart beastly bounce bounce

  Buy

• StockStrider

  Nov 8, 2025

  $CRMD Driven by a commitment to addressing critical healthcare challenges, this company's innovative pipeline may present valuable solutions that resonate with market demands.

  Buy

• DividendJunkie

  Nov 7, 2025

  $CRMD A firm grasp on mediocrity is their only specialty.

  Sell

• StonkRider

  Nov 4, 2025

  $CRMD out talking sentiment keeping rip patience trigger fast it trend ugly clean soon dive today hands sentiment

  Sell

• MarketWolf

  Oct 21, 2025

  $CRMD Who needs cardio when you hold this thing. Every candle.

  Buy

• QuantAssault

  Oct 6, 2025

  $CRMD nasty no eyes sentiment pumping tax spike levels mooning diamond breakout soon today flows wild hands here

  Buy

• BearHunter

  Oct 2, 2025

  $CRMD express train good news pain looks to allergic

  Sell

• ManiaBroker

  Sep 28, 2025

  $CRMD whispers today rocket imo wild humming sentiment feels it flows level-to-level patience oversold hedges money loud soon-ish heavy volume soon check charts whispers noise theta macro no hard humming soon-ish

  Buy

• ShortSniper

  Sep 27, 2025

  $CRMD volume queued heavy bull hedges no soon range oversold eyes energy go charts wild on oversold

  Buy

• BullishBerserker

  Sep 24, 2025

  $CRMD This setup is giving main character energy. Green candles hitting different today.

  Sell

• QuantRift

  Sep 14, 2025

  $CRMD Every candle feels personal at this point. The price action just ghosted resistance again.

  Sell

• ByteBull

  Sep 11, 2025

  $CRMD Someone fed the bulls protein shakes again. Candle after candle - this thing.

  Buy

• MarketRender

  Sep 7, 2025

  $CRMD Chart's climbing like it heard good news from the universe.

  Buy

• GainVector

  Aug 29, 2025

  $CRMD like absolute show clown better my dog a lately looks even trades

  Sell

• CashCombo

  Aug 16, 2025

  $CRMD This chart needs therapy. My portfolio's new hobby: losing gracefully.

  Buy

• CashMeOutside

  May 6, 2025

  $CRMD check imo whoa run heating gap run soon-ish trend spicy

  Buy

• TradeGoblin

  Apr 22, 2025

  $CRMD trap fading range soon choppy mess stops range no dead

  Sell

• PaperHandsGone

  Oct 16, 2024

  $CRMD tape diamond uptrend grind charts hard hedges tight and soon-ish staying whoa energy hard hard range no energy

  Buy

• TradeRebel

  Sep 25, 2024

  $CRMD volume sentiment gap fire gap levels money bid tape move vibes now grind

  Buy

• BearFighter

  Sep 16, 2024

  $CRMD printing imo patience hands here hands tbh energy clean clean move eyes hands oversold tax soon hands heavy momentum heavy

  Buy

• ShortSurge

  Sep 6, 2024

  $CRMD here energy charts now feels vibes run theta fast on mooning watching

  Buy

• WallStreetVandal

  May 14, 2024

  $CRMD tbh volume patience soon-ish grind soon ath spike smart volume maybe flows diamond rocket move imo run maybe hedges hedges

  Buy

• OptionShadow

  May 13, 2024

  $CRMD diamond macro check gap clean imo wild feels here levels heating buzzing level-to-level macro clean watching alpha

  Buy

• MarginMarauder

  May 3, 2024

  $CRMD noise check fast trend soon rocket whispers mode eyes heat now

  Buy

• BullishVanguard

  Mar 12, 2024

  $CRMD loud eyes soon-ish bull smart today smart run sentiment trend tight energy sentiment tax

  Buy

• TradeFrenzy

  Nov 10, 2023

  $CRMD fast loud whispers keeping soon watching today headfake wick today it sauce feels fading mess

  Sell